Administrative Core A
Administrative Core A
批准号:
10891051
负责人:
DAVID S METZGER
金额:
$24.38万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-03-15 至 2025-01-31
关键词:
Acquired Immunodeficiency SyndromeAddressAdvisory CommitteesAreaAwardBasic ScienceBehavioralBehavioral MechanismsBehavioral SciencesBiologicalBiological Specimen BanksBudgetsBusinessesCareer MobilityCharacteristicsCollaborationsCommunicationCommunitiesCommunity OutreachDevelopmentEducationEducation and OutreachEnsureEnvironmentEpidemiologyEquipment and SuppliesEvaluationFosteringFundingFutureHIVHIV riskHIV therapyHIV/AIDSHuman ResourcesIncidenceIndividualInfectionInformation DisseminationInternationalInvestmentsJointsLaboratoriesLeadershipMedicalMental HealthMental disordersMentorsMissionModelingMonitorNational Institute of Mental HealthOutcomeParticipantPediatric HospitalsPennsylvaniaPerformancePersonsPhiladelphiaPlayPoliciesProceduresProcessResearchResearch ActivityResearch DesignResearch InfrastructureResearch PersonnelResearch PriorityResearch SupportResearch TrainingResource SharingResourcesRoleSafetySchoolsScientistSeriesSocial SciencesStrategic PlanningStructureTrainingUnderrepresented MinorityUnited States National Institutes of HealthUniversitiesWomanWorkbehavioral and social sciencebiobehaviorcareer developmentco-infectioncohesioncollaborative environmentcollaboratorycommunity engagementcomorbiditycostdiversity and inclusionexperienceimplementation scienceimprovedinnovationinterdisciplinary collaborationlensmeetingsnext generationorganizational structureoutreachoutreach programprogramspsychologicsoundsynergism
中文摘要
核心A:摘要/总结
核心A提供领导、管理、组织结构、财政监督和科学指导,
宾夕法尼亚心理健康艾滋病研究中心(PMHARC),使其能够履行其核心使命,以改变如何
同时患有精神疾病和艾滋病毒的人得到治疗和管理,这是一个明确的重点,目前没有任何人追求
NIMH艾滋病研究中心(ARC)PMHARC的独特之处在于:1)它的科学重点是心理健康问题
通过基础、生物、社会和行为科学的整合,
和标本储存库和状态作为唯一的行为ARC与实验室和生物行为标记
3)它与CFAR为PMHARC试点项目开发了一个成功的共同供资模式;以及4)它作为
NIMH联合研讨会系列中唯一与NIMH神经ARC合作的NIMH行为ARC。的
中心和核心A由一名董事和两名联席董事领导,他们具有特殊和互补的优势,
在管理,研究和培训以及共病精神疾病/艾滋病毒研究方面的经验。PMHARC
坐落在一个最佳的智力和资源环境,其中包括强大的和备受好评的
心理健康和艾滋病毒研究社区在宾夕法尼亚州/CHOP/Wistar连续校园。通过核心
PMHARC将继续优化那些患有共病的患者的精神,行为和医疗结果。
精神疾病/艾滋病毒,并阐明这些背后的生物,心理和行为机制
结合疾病和治疗。核心A创造了一个促进沟通的互动环境,
中心各组成部分和参与者之间以及与相关学校之间的协作和协同作用,
宾夕法尼亚大学/CHOP/Wistar的部门,中心和研究所,包括CFAR,CTSA,Delaney Collaboratories,
Wistar和Temple,以及其他ARC。核心A将参与并负责:1)协调跨学科
和合作的心理健康/艾滋病毒研究; 2)鼓励,支持和指导新的,既定的,
过渡期研究者关注精神疾病/HIV共病和相关共病; 3)开发
充满活力和反应迅速的战略规划、监测和评估流程以及全面的政策
4)管理财务事务; 5)开展教育和社区外展计划; 6)
促进其他ARC之间的国家联系;以及7)支持积极的社区咨询委员会(CAB)。
核心A还包括3名顾问、执行委员会(EC)、内部咨询委员会(IAB)、外部咨询委员会(IAB)、
委员会(EAC),研究创新和多样性委员会(RIDC)和CAB。该结构明确
目的是进行持续监测和评价,以优化效率和响应能力。
在前两个周期,PMHARC在以下方面取得了令人印象深刻的进展:推进多样性/包容性;
艾滋病毒/心理健康综合研究的调查人员和促进研究基础设施;确定,
指导和促进早期研究人员(ESI)的职业发展;并制作令人印象深刻的
试点奖励计划的投资回报率。
英文摘要
CORE A: Abstract/Summary
Core A provides leadership, management, organizational structure, fiscal oversight, and scientific direction to
the Penn Mental Health AIDS Research Center (PMHARC), enabling it to fulfill its core mission to transform how
people with both mental illness and HIV are treated and managed, an explicit focus not currently pursued by any
other NIMH AIDS Research Center (ARC). PMHARC is unique in: 1) its scientific focus on mental health issues
in HIV through an integration of basic, biological and social and behavioral sciences; 2) its unique behavioral
and specimen repository and status as the only Behavioral ARC with a Laboratory and Biobehavioral Markers
Core; 3) its development of a successful co-funding model with CFAR for PMHARC pilots; and 4) its status as
the only NIMH Behavioral ARC collaborating with the NIMH Neuro ARCs in the NIMH Joint Seminar Series. The
Center and Core A is led by a Director and two Co-Directors with exceptional and complementary strengths and
experience in administration, research, and training and in the study of comorbid mental illness/HIV. PMHARC
is located in an optimal intellectual and resource environment, which encompasses robust and well-regarded
mental health and HIV research communities on the Penn/CHOP/Wistar contiguous campuses. Through Core
A, PMHARC will continue to optimize psychiatric, behavioral, and medical outcomes for those with comorbid
mental illness/HIV and elucidate the biological, psychological, and behavioral mechanisms underlying these
combined illnesses and treatments. Core A has created an interactive environment that fosters communication,
collaboration, and synergy among Center components and participants, as well as with the relevant schools,
departments, centers, and institutes at Penn/CHOP/Wistar including CFAR, CTSA, Delaney Collaboratories at
Wistar and Temple, and other ARCs. Core A will be engaged and responsible for: 1) coordinating interdisciplinary
and collaborative mental health/HIV research; 2) encouraging, supporting, and mentoring new, established, and
transitional investigators to focus on comorbid mental illness/HIV, and related comorbidities; 3) developing
vibrant and responsive Strategic Planning, Monitoring, and Evaluation Processes and comprehensive Policies
and Procedures; 4) managing fiscal matters; 5) conducting educational and community outreach programs; 6)
fostering national linkages among other ARCs; and 7) supporting an active Community Advisory Board (CAB).
Core A also includes 3 Consultants, Executive Committee (EC), Internal Advisory Board (IAB), External Advisory
Committee (EAC), Research Innovation and Diversity Committee (RIDC), and CAB. This structure is explicitly
intended to allow for continuous monitoring and evaluation in order to optimize efficiencies and responsiveness.
In its first two cycles, PMHARC has made impressive progress in: advancing Diversity/ Inclusion; engaging
investigators in combined HIV/mental health research and promoting research infrastructure; identifying,
mentoring, and promoting career advancement of Early Stage Investigators (ESIs); and producing an impressive
return on investment of the pilot award program.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
-
批准号:10197865
-
项目类别:
-
资助金额:$167.85万
-
财政年份:2019
-
负责人:DAVID S METZGER
-
依托单位:
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
-
批准号:10436808
-
项目类别:
-
资助金额:$165.25万
-
财政年份:2019
-
负责人:DAVID S METZGER
-
依托单位:
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
-
批准号:10654008
-
项目类别:
-
资助金额:$162.12万
-
财政年份:2019
-
负责人:DAVID S METZGER
-
依托单位:
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
-
批准号:10004224
-
项目类别:
-
资助金额:$51.51万
-
财政年份:2019
-
负责人:DAVID S METZGER
-
依托单位:
Rapid initiation of buprenorphine/naloxone to optimize MAT utilization in Philadelphia
-
批准号:9896726
-
项目类别:
-
资助金额:$74.62万
-
财政年份:2018
-
负责人:DAVID S METZGER
-
依托单位:
Core B: Developmental core
-
批准号:10090663
-
项目类别:
-
资助金额:$43.91万
-
财政年份:2013
-
负责人:DAVID S METZGER
-
依托单位:
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta
-
批准号:7835556
-
项目类别:
-
资助金额:$31.44万
-
财政年份:2009
-
负责人:DAVID S METZGER
-
依托单位:
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta
-
批准号:7687184
-
项目类别:
-
资助金额:$36.86万
-
财政年份:2009
-
负责人:DAVID S METZGER
-
依托单位:
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta
-
批准号:8261981
-
项目类别:
-
资助金额:$28.6万
-
财政年份:2009
-
负责人:DAVID S METZGER
-
依托单位:
Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta
-
批准号:8085908
-
项目类别:
-
资助金额:$30.25万
-
财政年份:2009
-
负责人:DAVID S METZGER
-
依托单位:
Behavioral & Social Sciences
-
批准号:7684973
-
项目类别:
-
资助金额:$23.48万
-
财政年份:2009
-
负责人:DAVID S METZGER
-
依托单位:
Core--Behavioral & Social Sciences Facility
-
批准号:7650391
-
项目类别:
-
资助金额:$21.57万
-
财政年份:2008
-
负责人:DAVID S METZGER
-
依托单位:
Core--Behavioral & Social Sciences Facility
-
批准号:7456546
-
项目类别:
-
资助金额:$25.35万
-
财政年份:2007
-
负责人:DAVID S METZGER
-
依托单位:
Penn prevention clinical trials unit
-
批准号:7560047
-
项目类别:
-
资助金额:$61.33万
-
财政年份:2007
-
负责人:DAVID S METZGER
-
依托单位:
Penn prevention clinical trials unit
-
批准号:8414863
-
项目类别:
-
资助金额:$60.66万
-
财政年份:2007
-
负责人:DAVID S METZGER
-
依托单位:
Penn prevention clinical trials unit
-
批准号:7341139
-
项目类别:
-
资助金额:$156.85万
-
财政年份:2007
-
负责人:DAVID S METZGER
-
依托单位:
Penn prevention clinical trials unit
-
批准号:7098383
-
项目类别:
-
资助金额:$122.86万
-
财政年份:2007
-
负责人:DAVID S METZGER
-
依托单位:
Penn prevention clinical trials unit
-
批准号:8007378
-
项目类别:
-
资助金额:$62.28万
-
财政年份:2007
-
负责人:DAVID S METZGER
-
依托单位:
Penn prevention clinical trials unit
-
批准号:8208122
-
项目类别:
-
资助金额:$61.63万
-
财政年份:2007
-
负责人:DAVID S METZGER
-
依托单位:
Penn prevention clinical trials unit
-
批准号:7751226
-
项目类别:
-
资助金额:$60.82万
-
财政年份:2007
-
负责人:DAVID S METZGER
-
依托单位:
海外基金